John Gargiulo to lead Daiichi Sankyo in the US
pharmafile | April 6, 2011 | Appointment | Sales and Marketing | appointment, sales and marketing
Daiichi Sankyo has appointed John Gargiulo as its president and chief executive in the US.
He succeeds Joseph Pieroni who is retiring after leading Daiichi Sankyo Group’s US commercial operations for the past 14 years.
John joined Sankyo in 1995 and most recently served as senior vice president of commercial operations, overseeing Daiichi Sankyo’s US marketing, supply chain, managed markets and new product planning.
He currently serves on the board at US industry body PhRMA and prior to joining Daiichi Sankyo, he held several positions at Lederle Laboratories.
“John’s experiences within the pharmaceutical industry for the past 25 years have prepared him well for his new role and responsibility,” said Joseph Pieroni.
“He has been instrumental in building and shaping the company since its inception in 1996, and has touched nearly every aspect of our business operations. His broad industry experience enabled him to learn and grow the commercial operations organisation.”
Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …






